Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors

NCT06781983 is registered in ClinicalTrials.gov with Innate Pharma as lead sponsor.

NCT NCT06781983
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06781983 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors
Lead sponsor
Innate Pharma
Phase
Phase 1
Overall status
Active, not recruiting
Start date
January 24, 2025
Completion date
April 30, 2029
Enrollment
145 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumors